1. Anthracycline antibiotics in cancer therapy: focus on drug resistance;Booser;Drugs,1994
2. NIOSH, NIOSH Alert-Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Setting, National Institute for Occupational Safety and Health. Centers for Disease Control and Prevention, Cincinnati, 2004.
3. IARC, Some Antineoplastic and Immunosuppressive Agents, Lyon, 1981. http://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Some-Antineoplastic-And-Immunosuppressive-Agents-1981 (accessed October 25, 2019).
4. IARC, Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1–42, IARC, Lyon, 1987. http://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-Supplements/Overall-Evaluations-Of-Carcinogenicity-An-Updating-Of-IARC-Monographs-Volumes-1%E2%80%9342-1987 (accessed October 25, 2019).
5. IARC, Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents, Lyon, 2000. http://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Some-Antiviral-And-Antineoplastic-Drugs-And-Other-Pharmaceutical-Agents-2000 (accessed October 25, 2019).